MedTrace Logo

Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma

NCT01284439 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2011-01-27

No results posted yet for this study

Summary

To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.

Conditions

Interventions

DRUG

hydroxypropylmethylcellulose

TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month

DRUG

sodium hyaluronate

QID to every 2 hous, 1-2 drops per each time, duration 1 month

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • AssocProf Pinnita Tanthuvanit, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-02-29

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284439 on ClinicalTrials.gov